HEM Hemosense

HemoSense, Inc. (AMEX:HEM) today announced that William H. Dippel, 60, will join the Company as executive vice president, operations and research & development on October 30, 2006. Mr. Dippel replaces Maria C. Navarro, who resigned in August 2006 to pursue other business opportunities. Mr. Dippel and HemoSense president and CEO Jim Merselis previously were colleagues at Boehringer Mannheim Corporation, where they collaborated on the development and marketing of point-of-care medical devices. �With more than 32 years of senior management experience in the medical device and diagnostic sectors, Bill will be able to hit the ground running at HemoSense,� said Mr. Merselis. �Earlier in his career Bill played a fundamental role in the development of a first-generation PT/INR monitoring system, and subsequently has demonstrated the ability to ramp production, improve manufacturing processes and control costs. His track record in operations and product development makes Bill an excellent fit for HemoSense. We look forward to drawing on his extensive experience, and I look forward to working with him once again.� Most recently, Mr. Dippel was vice president of operations at Micro Therapeutics Inc., an endovascular medical device company that was recently acquired by ev3, Inc. From 2001 to 2004, he served as vice president of R&D and operations at Conceptus, Inc., a medical device company focused on women�s health, where he spearheaded the development of that company�s manufacturing and operating systems. Prior to that, he served as vice president of operations at PercuSurge, Inc. (now a division of Medtronic, Inc.) and at Boston Scientific Corporation�s Target Therapeutics division. He has also held positions of increasing responsibility in operations and product development at Boehringer Mannheim GmbH (now Roche Diagnostics), Ciba Corning Diagnostics Corporation Spectrum Technology, Inc., and Johnson & Johnson. Mr. Dippel received a bachelor�s of science degree in mechanical engineering from California State Polytechnic University, Pomona. About HemoSense HemoSense develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatio� system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient�s warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.hemosense.com. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary, expectations and are subject to risks and uncertainties which may cause the actual results to differ materially from the statements contained herein. Further information on the Company's business and risk factors are detailed in its filings with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2006 filed on August 11, 2006. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. HemoSense� and INRatio� are registered trademarks of HemoSense, Inc. HemoSense, Inc. (AMEX:HEM) today announced that William H. Dippel, 60, will join the Company as executive vice president, operations and research & development on October 30, 2006. Mr. Dippel replaces Maria C. Navarro, who resigned in August 2006 to pursue other business opportunities. Mr. Dippel and HemoSense president and CEO Jim Merselis previously were colleagues at Boehringer Mannheim Corporation, where they collaborated on the development and marketing of point-of-care medical devices. "With more than 32 years of senior management experience in the medical device and diagnostic sectors, Bill will be able to hit the ground running at HemoSense," said Mr. Merselis. "Earlier in his career Bill played a fundamental role in the development of a first-generation PT/INR monitoring system, and subsequently has demonstrated the ability to ramp production, improve manufacturing processes and control costs. His track record in operations and product development makes Bill an excellent fit for HemoSense. We look forward to drawing on his extensive experience, and I look forward to working with him once again." Most recently, Mr. Dippel was vice president of operations at Micro Therapeutics Inc., an endovascular medical device company that was recently acquired by ev3, Inc. From 2001 to 2004, he served as vice president of R&D and operations at Conceptus, Inc., a medical device company focused on women's health, where he spearheaded the development of that company's manufacturing and operating systems. Prior to that, he served as vice president of operations at PercuSurge, Inc. (now a division of Medtronic, Inc.) and at Boston Scientific Corporation's Target Therapeutics division. He has also held positions of increasing responsibility in operations and product development at Boehringer Mannheim GmbH (now Roche Diagnostics), Ciba Corning Diagnostics Corporation Spectrum Technology, Inc., and Johnson & Johnson. Mr. Dippel received a bachelor's of science degree in mechanical engineering from California State Polytechnic University, Pomona. About HemoSense HemoSense develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatio(R) system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient's warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.hemosense.com. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary, expectations and are subject to risks and uncertainties which may cause the actual results to differ materially from the statements contained herein. Further information on the Company's business and risk factors are detailed in its filings with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2006 filed on August 11, 2006. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. HemoSense(R) and INRatio(R) are registered trademarks of HemoSense, Inc.